RTSN · Forms 3, 4, 5
Insider trades at Retension Pharmaceuticals
2 insiders bought $370K of Retension Pharmaceuticals stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for Retension Pharmaceuticals (RTSN) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Robert Wong | VP, Chief Accounting Officer | Options or other derivatives | Form 4 | ||||
| Robert Wong | VP, Chief Accounting Officer | Became an insider (Form 3) | Form 3 | ||||
| Eric L. Keller | Chief executive officer | Options or other derivatives | Form 4 | ||||
| B Group, Inc. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Eric L. Keller | Chief executive officer | Buy | 20,800 | $12.00 | $250K | Form 4 | |
| Eric L. Keller | Chief executive officer | Conversion | 9,662 | Form 4 | |||
| Eric L. Keller | Chief executive officer | Conversion | 31,368 | Form 4 | |||
| Paul Sweetnam | Chief scientific officer | Conversion | 4,026 | Form 4 | |||
| Paul Sweetnam | Chief scientific officer | Conversion | 2,640 | Form 4 | |||
| Donald Olds | Director | Conversion | 5,637 | Form 4 | |||
| Pavan Cheruvu | Director | Options or other derivatives | Form 4 | ||||
| Sabine Bisson | Chief operating officer | Conversion | 1,611 | Form 4 | |||
| Sabine Bisson | Chief operating officer | Conversion | 2,504 | Form 4 | |||
| Franklin M Berger | Director | Conversion | 12,517 | Form 4 | |||
| Franklin M Berger | Director | Buy | 10,000 | $12.00 | $120K | Form 4 | |
| Michael J Berendt | Director | Conversion | 4,026 | Form 4 | |||
| Michael J Berendt | Director | Conversion | 2,640 | Form 4 | |||
| Pavan Cheruvu | Director | Became an insider (Form 3) | Form 3 | ||||
| Michael J Berendt | Director | Options or other derivatives | Form 4 | ||||
| Donald Olds | Director | Options or other derivatives | Form 4 | ||||
| Franklin M Berger | Director | Options or other derivatives | Form 4 | ||||
| Alexander Duke Schwartz | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Paul Sweetnam | Chief Scientific Officer | Became an insider (Form 3) | Form 3 | ||||
| Alison D. Schecter | Chief Medical Officer | Became an insider (Form 3) | Form 3 | ||||
| Donald Olds | Director | Became an insider (Form 3) | Form 3 | ||||
| Eric L. Keller | Chief Executive Officer | Became an insider (Form 3) | Form 3 | ||||
| Sabine Bisson | Chief Operating Officer | Became an insider (Form 3) | Form 3 | ||||
| Franklin M Berger | Director | Became an insider (Form 3) | Form 3 | ||||
| Michael J Berendt | Director | Became an insider (Form 3) | Form 3 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.